Biologic and clinical evaluation of high intermittent dose all trans retinoic acid (ATRA) in refractory multiple myeloma (MM) patients (PTS).

被引：0
|
作者：
Hussein, MA [1 ]
Bocock, K [1 ]
Bloom, T [1 ]
Finke, J [1 ]
Rybicki, L [1 ]
Scott, R [1 ]
Bukowski, RM [1 ]
机构：
[1] Cleveland Clin, Ctr Canc, Cleveland, OH 44106 USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
444
引用
收藏
页码：108A / 109A
页数：2
相关论文
共 50 条
  • [21] Prolonged third remission in a patient with acute promyelocytic leukemia after consolidation chemotherapy with intermittent intermediate dose Ara-C and maintenance with intermittent all-trans retinoic acid (ATRA)
    Laczika, K
    Mitterbauer, G
    Weltermann, A
    Knöbl, P
    Thalhammer-Scherrer, R
    Haas, OA
    Lechner, K
    Jaeger, U
    LEUKEMIA & LYMPHOMA, 2000, 36 (5-6) : 625 - 629
  • [22] Effect of all-trans retinoic acid (ATRA) on differentiation of dendritic and immature myeloid cells in cancer patients
    Gabrilovich, Dmitry I.
    Mirza, Noweeda
    Fricke, Ingo
    Williams, Nickolas
    Antonia, Scott
    Fishman, Mayer
    CANCER RESEARCH, 2006, 66 (08)
  • [23] All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma
    Musto, P
    Sajeva, MR
    Sanpaolo, G
    DArena, G
    Scalzulli, PR
    Carotenuto, M
    HAEMATOLOGICA, 1997, 82 (03) : 354 - 356
  • [24] MULTIPLE MYELOMA CELLS UNDERGO DIFFERENTIATION UPON EXPOSURE TO ROSIGLITAZONE AND ALL-TRANS RETINOIC ACID
    Huang, H. W.
    Wu, D. P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 609 - 609
  • [25] Induction of Chemoresistance by All-Trans Retinoic Acid via a Noncanonical Signaling in Multiple Myeloma Cells
    Liu, Zhiqiang
    Li, Tao
    Jiang, Kesheng
    Huang, Qiaoli
    Chen, Yicheng
    Qian, Feng
    PLOS ONE, 2014, 9 (01):
  • [26] Combination of melphalan (M), ascorbic acid (A) and trisenox (T) (MAT) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM).
    Chanan-Khan, AA
    Miller, K
    Sirinivasan, S
    McCarthy, P
    Alam, A
    Bernstein, ZP
    Czuczman, MS
    BLOOD, 2003, 102 (11) : 389B - 389B
  • [27] Velcade (Vel), Doxil® (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM).
    Chanan-Khan, AA
    Miller, K
    Srinivasan, S
    David, S
    McCarthy, P
    Alam, A
    Bernstein, ZP
    Czuczman, MS
    BLOOD, 2003, 102 (11) : 389B - 389B
  • [28] Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia Why National Guidelines May Not be Followed
    Mogasala, Nagendra
    Devata, Sumana
    Perissinotti, Anthony
    Bixby, Dale
    BLOOD, 2014, 124 (21)
  • [29] Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)
    Badros, A. Z.
    Philip, S.
    Niesvizk, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J. J.
    Burger, A.
    Baer, M. R.
    Egorin, M. J.
    Grant, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations.
    Kyrtsonis, MC
    Sachanas, S
    Vassilakopoulos, TP
    Kafassi, N
    Tzenou, T
    Papadogiannis, A
    Kalpadakis, C
    Antoniadis, AG
    Dimopoulou, MN
    Angelopoulou, MK
    Siakantaris, MP
    Dimitriadou, EM
    Kokoris, SI
    Plata, E
    Tsaftaridis, P
    Panayiotidis, P
    Pangalis, GA
    BLOOD, 2005, 106 (11) : 382B - 382B
12345